Thalia Therapeutics - CEO Interview
Reach
Latest announcements
Announcement summary
Thalia Therapeutics - CEO Interview
Our CEO, Dr David Solomon, recently spoke with BioHub about how Thalia Therapeutics is developing differentiated next-generation RNA therapeutics.
The interview also discusses our novel approach to cardiovascular disease, at a time when interest in genetically targeted therapies continues to grow, highlighted by recent research published in the New England Journal of Medicine.
Ask a question
Your question will be visible to everyone.
Investor Q&As
Start the conversation
Ask Thalia Therapeutics a question about this announcement.